GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » PS Ratio

Coherus BioSciences (Coherus BioSciences) PS Ratio

: 0.81 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Coherus BioSciences's share price is $2.145. Coherus BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.66. Hence, Coherus BioSciences's PS Ratio for today is 0.81.

The historical rank and industry rank for Coherus BioSciences's PS Ratio or its related term are showing as below:

CHRS' s PS Ratio Range Over the Past 10 Years
Min: 0.66   Med: 5.61   Max: 746.3
Current: 0.78

During the past 12 years, Coherus BioSciences's highest PS Ratio was 746.30. The lowest was 0.66. And the median was 5.61.

CHRS's PS Ratio is ranked better than
92.99% of 998 companies
in the Biotechnology industry
Industry Median: 9.06 vs CHRS: 0.78

Coherus BioSciences's Revenue per Sharefor the three months ended in Dec. 2023 was $0.82. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.66.

Warning Sign:

Coherus BioSciences Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Coherus BioSciences was 0.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -21.70% per year.

During the past 12 years, Coherus BioSciences's highest 3-Year average Revenue per Share Growth Rate was 481.40% per year. The lowest was -80.30% per year. And the median was 2.40% per year.

Back to Basics: PS Ratio


Coherus BioSciences PS Ratio Historical Data

The historical data trend for Coherus BioSciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 3.05 3.69 2.91 1.22

Coherus BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.91 1.90 1.54 1.22

Competitive Comparison

For the Biotechnology subindustry, Coherus BioSciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's PS Ratio falls into.



Coherus BioSciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Coherus BioSciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.145/2.664
=0.81

Coherus BioSciences's Share Price of today is $2.145.
Coherus BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.66.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Coherus BioSciences  (NAS:CHRS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Coherus BioSciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (Coherus BioSciences) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009